Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Sponsor
Oncology Institute of Southern Switzerland
Study ID
NCT03274778
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Ruxolitinib will be dispensed to patients candidate to prostatectomy immediately after histological diagnosis of prostate adenocarcinoma. The treatment will be given for 28 days followed by a prostatectomy thereafter. Tumor material and blood samples will be analysed before, during and after the treatment with Ruxolitinib.

Key Dates

Start date
Sep 1, 2017
Status verified
Mar 2020
Primary completion
Mar 24, 2020
Completion
Mar 24, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    Oral administration of Ruxolitinib 20mg BID for 28 consecutive days

Primary Outcome Measure

Tumor immune response [ Time Frame: 9 wks ]

Related Studies